Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome
Gerwin Huls*, Dana A. Chitu, Lidwine Tick, Rinske Boersma, Dimitri Breems, Alexandra Herbers, Saskia K. Klein, Suzan de Jonge, Peter E. Westerweel, Marjan Cruijsen, Mels Hoogendoorn, Marlous Cuijpers, Dries Deeren, Benjamin Bailly, Otto Visser, Anna van Rhenen, Eduard F.M. Posthuma, Peter J.M. Valk, Jacqueline Cloos, Emanuele AmmatunaJeannine M. Refos, R. Fakkert, Bob Löwenberg, Gert J. Ossenkoppele
Duik in de onderzoeksthema's van 'Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome'. Samen vormen ze een unieke vingerafdruk.